FSFrancis G. Spinale

Francis G. Spinale

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francis G. Spinale has a total of 122 co-authors. Here are the top co-authors by number of shared publications:

  • Robert E. Stroud

    Division of Cardiothoracic Surgery, Medical University of South Carolina

    18 shared publications
  • Rupak Mukherjee

    Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, South Carolina, Ralph H. Johnson Veterans’ Association Medical Center, Charleston, South Carolina

    15 shared publications
  • Jennifer A. Dixon

    Division of Cardiothoracic Surgery, Medical University of South Carolina and Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA

    8 shared publications
  • Christine N. Koval

    Division of Cardiothoracic Surgery, Medical University of South Carolina and Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina

    7 shared publications
  • John S. Ikonomidis

    Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, South Carolina, Ralph H. Johnson Veterans’ Association Medical Center, Charleston, South Carolina

    6 shared publications
  • Scott T. Reeves

    Department of Anesthesia, Medical University of South Carolina and the Ralph H. Johnson VA Medical Center, Charleston, SC

    6 shared publications

Latest Publications

  • Aortic Dilatation With Bicuspid Aortic Valves: Cusp Fusion Correlates to Matrix Metalloproteinases and Inhibitors

    by John S. Ikonomidis, Jean Marie Ruddy, Stewart M. Benton, Jazmine Arroyo, Theresa A. Brinsa, Robert E. Stroud, Ahmed Zeeshan, Joseph E. Bavaria, Joseph H. Gorman, Robert C. Gorman, et al.


  • Open Access

    Hemodynamics and myocardial blood flow patterns after placement of a cardiac passive restraint device in a model of dilated cardiomyopathy

    by Jennifer A. Dixon, Amy M. Goodman, William F. Gaillard, William T. Rivers, Richard A. McKinney, Rupak Mukherjee, Nathaniel L. Baker, John S. Ikonomidis, Francis G. Spinale


  • Direct regulation of membrane type 1 matrix metalloproteinase following myocardial infarction causes changes in survival, cardiac function, and remodeling

    by Juozas A. Zavadzkas, Rupak Mukherjee, William T. Rivers, Risha K. Patel, Evan C. Meyer, Laurel E. Black, Richard A. McKinney, J. Marshall Oelsen, Robert E. Stroud, Francis G. Spinale

    The membrane type 1 matrix metalloproteinase (MT1-MMP) is increased in left ventricular (LV) failure. However, the direct effects of altered MT1-MMP levels on survival, LV function, and geometry following myocardial infarction (MI) and the proteolytic substrates involved in this process remain unclear. MI was induced in mice with cardiac-restricted overexpression of MT1-MMP (MT1-MMPexp; full length human), reduced MT1-MMP expression (heterozygous; MT1-MMP+/−), and wild type. Post-MI survival was reduced with MT1-MMPexp and increased with MT1-MMP+/− compared with WT. LV ejection fraction was lower in the post-MI MT1-MMPexp mice compared with WT post-MI and was higher in the MT1-MMP+/− mice. In vivo localization of MT1-MMP using antibody-conjugated microbubbles revealed higher MT1-MMP levels post-MI, which were the highest in the MT1-MMPexp group and the lowest in the MT1-MMP+/− group. LV collagen content within the MI region was higher in the MT1-MMPexp vs. WT post-MI and reduced in the MT1-MMP+/− group. Furthermore, it was demonstrated that MT1-MMP proteolytically processed the profibrotic molecule, latency-associated transforming growth factor-1-binding protein (LTBP-1), and MT1-MMP-specific LTBP-1 proteolytic activity was increased by over fourfold in the post-MI MT1-MMPexp group and reduced in the MT1-MMP+/− group, which was directionally paralleled by phospho-Smad-3 levels, a critical signaling component of the profibrotic transforming growth factor pathway. We conclude that modulating myocardial MT1-MMP levels affected LV function and matrix structure, and a contributory mechanism for these effects is through processing of profibrotic signaling molecules. These findings underscore the diversity of biological effects of certain MMP types on the LV remodeling process.


  • Targeted Regional Injection of Biocomposite Microspheres Alters Post–Myocardial Infarction Remodeling and Matrix Proteolytic Pathways

    by Jennifer A. Dixon, Robert C. Gorman, Robert E. Stroud, Rupak Mukherjee, Evan C. Meyer, Nathaniel L. Baker, Masato Morita, Hirotsugu Hamamoto, Liam P. Ryan, Joseph H. Gorman, et al.

    Background—: Although localized delivery of biocomposite materials, such as calcium hydroxyapatite (CHAM), have been demonstrated to potentially attenuate adverse left ventricular (LV) remodeling after myocardial infarction (MI), the underlying biological mechanisms for this effect remain unclear. This study tested the hypothesis that targeted CHAM injections would alter proteolytic pathways (matrix metalloproteinases [MMPs] and tissue inhibitors of MMPs [TIMPs]) and would be associated with parameters of post-MI LV remodeling. Methods and Results—: MI was induced in adult sheep followed by 20 targeted injections of a total volume of 1.3 mL (n=6) or 2.6 mL of CHAM (n=5) or saline (n=13) and LV end-diastolic volume (EDV) and MMP/TIMP profiles in the MI region were measured at 8 weeks after MI. LV EDV decreased with 2.6 mL CHAM versus MI only (105.4±7.5 versus 80.6±4.2 respectively, P P =0.32). However, MI thickness increased by 2-fold in both CHAM groups compared with MI only ( P P 6-fold in both CHAM groups ( P P P P <0.05). Conclusions—: Differential effects on LV remodeling and MMP/TIMP profiles occurred with CHAM. Thus, targeted injection of a biocomposite material can favorably affect the post-MI remodeling process and therefore holds promise as a treatment strategy in and of itself, or as a matrix with potentially synergistic effects with localized pharmacological or cellular therapies.


    • 1 August 2011
      • Vol. 107  (4) , 150-2

    Stem cells and cardiac surgery- the road ahead.

    by Francis G Spinale, Jennifer A Dixon

  • Continuous Localized Monitoring of Plasmin Activity Identifies Differential and Regional Effects of the Serine Protease Inhibitor Aprotinin: Relevance to Antifibrinolytic Therapy

    by Daryl L Reust, Jennifer A Dixon, Richard A McKinney, Risha K Patel, William T Rivers, Rupak Mukherjee, Robert E Stroud, Karen Madden, Kevin Groves, Milind Rajopadhye, et al.

    Antifibrinolytic therapy, such as the use of the serine protease inhibitor aprotinin, was a mainstay for hemostasis after cardiac surgery. However, aprotinin was empirically dosed, and although the pharmacological target was the inhibition of plasmin activity (PLact), this was never monitored, off-target effects occurred, and led to withdrawn from clinical use. The present study developed a validated fluorogenic microdialysis method to continuously measure PLact and tested the hypothesis that standardized clinical empirical aprotinin dosing would impart differential and regional effects on PLact. Pigs (30 kg) were instrumented with microdialysis probes to continuously measure PLact in myocardial, kidney, and skeletal muscle compartments (deltoid) and then randomized to high-dose aprotinin administration (2 mKIU load/0.5 mKIU/hr infusion; n = 7), low-dose aprotinin administration (1 mKIU load/0.250 mKIU/hr infusion; n = 6). PLact was compared with time-matched vehicle (n = 4), and PLact was also measured in plasma by an in vitro fluorogenic method. Aprotinin suppressed PLact in the myocardium and kidney at both high and low doses, indicative that both doses exceeded a minimal concentration necessary for PLact inhibition. However, differential effects of aprotinin on PLact were observed in the skeletal muscle, indicative of different compartmentalization of aprotinin. Using a large animal model and a continuous method to monitor regional PLact, these unique results demonstrated that an empirical aprotinin dosing protocol causes maximal and rapid suppression in the myocardium and kidney and in turn would likely increase the probability of off-target effects and adverse events. Furthermore, this proof of principle study demonstrated that continuous monitoring of determinants of fibrinolysis might provide a novel approach for managing fibrinolytic therapy.


  • Myocardial Remodeling: Cellular and Extracellular Events and Targets

    by Jennifer A. Dixon, Francis G. Spinale

    The focus of this review is on translational studies utilizing large-animal models and clinical studies that provide fundamental insight into cellular and extracellular pathways contributing to post–myocardial infarction (MI) left ventricle (LV) remodeling. Specifically, both large-animal and clinical studies have examined the potential role of endogenous and exogenous stem cells to alter the course of LV remodeling. Interestingly, there have been alterations in LV remodeling with stem cell treatment despite a lack of long-term cell engraftment. The translation of the full potential of stem cell treatments to clinical studies has yet to be realized. The modulation of proteolytic pathways that contribute to the post-MI remodeling process has also been examined. On the basis of recent large-animal studies, there appears to be a relationship between stem cell treatment post-MI and the modification of proteolytic pathways, generating the hypothesis that stem cells leave an echo effect that moderates LV remodeling.


  • Open Access

    Determinants of Extracellular Matrix Remodelling are Differentially Expressed in Paediatric and Adult Dilated Cardiomyopathy

    by Tain-Yen Hsia, Jeremy M. Ringewald, Robert E. Stroud, Geoffrey A. Forbus, Scott M. Bradley, Wendy K. Chung, Francis G. Spinale

    Aims The left ventricular phenotype of idiopathic dilated cardiomyopathy (DCM) can appear similar in paediatric and adult patients. However, the aetiology of paediatric DCM is usually idiopathic, and often leads an aggressive clinical course. A structural underpinning of DCM is extracellular matrix changes, which are determined by a balance between matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs). This study tested the hypothesis that different MMP/TIMP profiles occur in paediatric and adult DCM patients. Methods and results Left ventricular samples from paediatric (age 9 ± 5 years; n = 10) and adult (age 62 ± 3 years; n = 20) DCM (at time of transplant) were subjected to an MMP/TIMP multiplex array and immunoassay in order to measure the MMP subclasses; collagenases (MMP−8, −13), gelatinases (MMP−2, −9), stromelysin/matrilysin (MMP−3, −7), membrane type (MT1‐MMP), as well as for the four known TIMPs. MMP−8 and −9 levels increased by over 150% (P < 0.05), whereas MMP−3 and −7 levels decreased by over 30% (P < 0.05) in paediatric DCM when compared with adult DCM. TIMP−1 and −2 levels increased two‐fold (P < 0.05), but TIMP‐3 fell by 41% (P < 0.05) in paediatric DCM. Myocardial levels of specific interleukins (IL‐1beta, IL‐2, IL‐8) were increased by approximately 50% in paediatric DCM. Conclusions These unique findings demonstrated that a specific MMP/TIMP profile occurs in paediatric DCM when compared with adult DCM, and that local cytokine induction may contribute to this process. These distinct differences in the determinants of myocardial matrix structure and function may contribute to the natural history of DCM in children.


  • Open Access

    Circulating matrix metalloproteinase levels after ventricular septal defect repair in infants

    by Tim C. McQuinn, Rachael L. Deardorff, Rupak Mukherjee, Anna Greta B. Taylor, Eric M. Graham, Andrew M. Atz, Geoffrey A. Forbus, Stacia M. DeSantis, Jennifer B. Young, Robert E. Stroud, et al.